Mercury Labs

{
  "main_header": {
    "sid": 287757,
    "name": "Mercury Labs",
    "stock_name": "Mercury Labs",
    "full_name": "Mercury Laboratories Ltd",
    "name_url": "stocks-analysis/mercury-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "800.00",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "800.00",
    "mcapval": "96.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 538964,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE947G01011",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": "96 ",
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/mercury-labs-287757-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Mercury Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-is-rated-sell-3792779",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/MercuryLaborato_mojoScore_3792779.png",
        "date": "2026-01-15 10:10:27",
        "description": "Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 January 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Why is Mercury Laboratories Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-mercury-laboratories-ltd-fallingrising-3792395",
        "imagepath": "",
        "date": "2026-01-15 00:46:30",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Mercury Laboratories Ltd has experienced a consistent decline over the past week, with its stock price dropping by 3.03%, which is significantly steeper than the Sensex’s 1.86% fall during the same period. Over the last month, the stock’s performance further deteriorated, falling 4.21% compared to the Sensex’s 2.21% decline. Year-to-date, the stock has marginally outperformed the benchmark, registering a smaller loss of 1.38% against the Sensex’s 2.16% drop. However, the longer-term picture remains less favourable, with the stock posting an 11.21% loss over the past year while the Sensex gained 9.00% in that timeframe.</p>\n<p>Despite some positive returns over three and five years, where Mercury Laboratories Ltd recorded gains of 5...."
      },
      {
        "title": "Mercury Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-is-rated-sell-3780555",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/MercuryLaborato_mojoScore_3780555.png",
        "date": "2026-01-04 10:10:04",
        "description": "Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 04 January 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Mercury Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-ltd-is-rated-sell-3768530",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MercuryLaborato_mojoScore_3768530.png",
        "date": "2025-12-24 20:23:35",
        "description": "Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 December 2025, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Mercury Laboratories: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mercury-laboratories-downgraded-to-sell-amid-technical-weakness-and-long-term-underperformance-3743119",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MercuryLaborato_mojoScore_3743119.png",
        "date": "2025-12-03 08:14:40",
        "description": "Mercury Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment following a detailed review of its quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent changes in the company’s evaluation metrics, providing investors with a comprehensive understanding of its current standing."
      },
      {
        "title": "How has been the historical performance of Mercury Labs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-mercury-labs-3742230",
        "imagepath": "",
        "date": "2025-12-02 22:57:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Over the past seven years, Mercury Labs’ net sales have shown a generally upward trend, rising from ₹55.52 crores in March 2019 to ₹75.10 crores in March 2025. The company experienced a notable jump in sales between March 2021 and March 2022, increasing from ₹68.60 crores to ₹57.92 crores, followed by stabilisation around the ₹75 crore mark in subsequent years. Despite minor fluctuations, the revenue base has remained relatively stable in the ₹75 crore range in the last three years.</p>\n<p>Operating profit margins, excluding other income, have seen some contraction, moving from 13.98% in March 2021 to 9.35% in March 2025. This decline reflects rising costs, particularly in employee expenses which increased from ₹7.83 crores in 2019 to ₹16.84 c..."
      },
      {
        "title": "Are Mercury Labs latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-mercury-labs-latest-results-good-or-bad-3698349",
        "imagepath": "",
        "date": "2025-11-13 19:33:52",
        "description": "Mercury Laboratories' latest financial results for Q2 FY26 reflect a complex operational landscape. The company reported a net profit of ₹1.64 crores, marking a significant year-on-year profit growth of 228.00% compared to ₹0.50 crores in the same quarter last year. This surge was primarily driven by a notable reduction in the effective tax rate, which fell from 37.42% in Q1 FY26 to 14.58% in Q2 FY26, contributing positively to the bottom line.\n\nRevenue for the quarter stood at ₹19.01 crores, indicating a sequential increase of 4.80% from ₹18.14 crores in Q1 FY26. However, the year-on-year revenue growth of 4.51% suggests that the topline performance remains modest for a pharmaceutical company, particularly in light of the previous quarter's sharp contraction of 12.20%. \n\nOperating margins were reported at 11.20%, which reflects a sequential decline of 1.81% from the previous quarter's 13.01%. This compress..."
      },
      {
        "title": "Mercury Laboratories Reports Improved Profitability Amidst Year-to-Date Stock Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mercury-laboratories-financial-trend-improves-from-flat-to-positive-with-rising-profit-after-tax-3697336",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MercuryLaborato_fintrenddot_3697336.png",
        "date": "2025-11-13 11:01:06",
        "description": "Mercury Laboratories has reported a profit after tax of Rs 1.64 crore for the quarter ending September 2025, with earnings per share at Rs 13.67. Despite recent quarterly success, the company faces challenges in year-to-date performance, contrasting with broader market gains, while showing long-term outperformance over several years."
      },
      {
        "title": "Mercury Laboratories Q2 FY26: Profit Surge Masks Underlying Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/mercury-laboratories-q2-fy26-profit-surge-masks-underlying-margin-pressures-3697643",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MercuryLaborato_quaterlyResult_3697643.png",
        "date": "2025-11-13 09:21:43",
        "description": "Mercury Laboratories Ltd., a Mumbai-based pharmaceutical manufacturer, reported a robust 69.07% quarter-on-quarter surge in net profit to ₹1.64 crores for Q2 FY26 (July-September 2025), marking its strongest quarterly performance in recent history. However, the impressive bottom-line growth conceals a more nuanced operational reality characterised by volatile margins and stagnant long-term growth, raising questions about the sustainability of this earnings momentum."
      }
    ],
    "total": 108,
    "sid": "287757",
    "stock_news_url": "https://www.marketsmojo.com/news/mercury-laboratories-287757"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "03-Jan-2026",
      "details": "Compliance certificate under Reg 74(5) SEBI(DP) Reg 2018 for the quarter ended on December 31 2025 is attached",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "25-Dec-2025",
      "details": "Intimation for Closure of Trading Window for the announcement unaudited Financial Results for the quarter and nine months ended on Dec 31 2025 is attached",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "17-Nov-2025",
      "details": "Intimation about additional charge assigned to Mr. Saurabh Mittal as VP-marketing & Sales is attached",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Mercury Laboratories Ltd has declared <strong>35%</strong> dividend, ex-date: 06 Aug 25",
          "dt": "2025-08-06",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Mercury Laboratories Ltd is Rated Sell

2026-01-15 10:10:27

Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 January 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Why is Mercury Laboratories Ltd falling/rising?

2026-01-15 00:46:30

Recent Price Movement and Market Comparison

Mercury Laboratories Ltd has experienced a consistent decline over the past week, with its stock price dropping by 3.03%, which is significantly steeper than the Sensex’s 1.86% fall during the same period. Over the last month, the stock’s performance further deteriorated, falling 4.21% compared to the Sensex’s 2.21% decline. Year-to-date, the stock has marginally outperformed the benchmark, registering a smaller loss of 1.38% against the Sensex’s 2.16% drop. However, the longer-term picture remains less favourable, with the stock posting an 11.21% loss over the past year while the Sensex gained 9.00% in that timeframe.

Despite some positive returns over three and five years, where Mercury Laboratories Ltd recorded gains of 5....

Read full news article

Mercury Laboratories Ltd is Rated Sell

2026-01-04 10:10:04

Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 04 January 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Mercury Laboratories Ltd is Rated Sell

2025-12-24 20:23:35

Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 December 2025, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Mercury Laboratories: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals

2025-12-03 08:14:40

Mercury Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment following a detailed review of its quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent changes in the company’s evaluation metrics, providing investors with a comprehensive understanding of its current standing.

Read full news article

How has been the historical performance of Mercury Labs?

2025-12-02 22:57:26

Revenue and Profitability Trends

Over the past seven years, Mercury Labs’ net sales have shown a generally upward trend, rising from ₹55.52 crores in March 2019 to ₹75.10 crores in March 2025. The company experienced a notable jump in sales between March 2021 and March 2022, increasing from ₹68.60 crores to ₹57.92 crores, followed by stabilisation around the ₹75 crore mark in subsequent years. Despite minor fluctuations, the revenue base has remained relatively stable in the ₹75 crore range in the last three years.

Operating profit margins, excluding other income, have seen some contraction, moving from 13.98% in March 2021 to 9.35% in March 2025. This decline reflects rising costs, particularly in employee expenses which increased from ₹7.83 crores in 2019 to ₹16.84 c...

Read full news article

Are Mercury Labs latest results good or bad?

2025-11-13 19:33:52

Mercury Laboratories' latest financial results for Q2 FY26 reflect a complex operational landscape. The company reported a net profit of ₹1.64 crores, marking a significant year-on-year profit growth of 228.00% compared to ₹0.50 crores in the same quarter last year. This surge was primarily driven by a notable reduction in the effective tax rate, which fell from 37.42% in Q1 FY26 to 14.58% in Q2 FY26, contributing positively to the bottom line. Revenue for the quarter stood at ₹19.01 crores, indicating a sequential increase of 4.80% from ₹18.14 crores in Q1 FY26. However, the year-on-year revenue growth of 4.51% suggests that the topline performance remains modest for a pharmaceutical company, particularly in light of the previous quarter's sharp contraction of 12.20%. Operating margins were reported at 11.20%, which reflects a sequential decline of 1.81% from the previous quarter's 13.01%. This compress...

Read full news article

Mercury Laboratories Reports Improved Profitability Amidst Year-to-Date Stock Challenges

2025-11-13 11:01:06

Mercury Laboratories has reported a profit after tax of Rs 1.64 crore for the quarter ending September 2025, with earnings per share at Rs 13.67. Despite recent quarterly success, the company faces challenges in year-to-date performance, contrasting with broader market gains, while showing long-term outperformance over several years.

Read full news article

Mercury Laboratories Q2 FY26: Profit Surge Masks Underlying Margin Pressures

2025-11-13 09:21:43

Mercury Laboratories Ltd., a Mumbai-based pharmaceutical manufacturer, reported a robust 69.07% quarter-on-quarter surge in net profit to ₹1.64 crores for Q2 FY26 (July-September 2025), marking its strongest quarterly performance in recent history. However, the impressive bottom-line growth conceals a more nuanced operational reality characterised by volatile margins and stagnant long-term growth, raising questions about the sustainability of this earnings momentum.

Read full news article

View All News